AI Article Synopsis

  • Epithelioid glioblastoma (Ep-GBM) is a rare and aggressive brain tumor variant, with a high recurrence rate and poor prognosis; there’s currently no established standard treatment for it.
  • In a study of 58 Ep-GBM cases, common symptoms included headaches and dizziness, and the median survival rates were 12.7 months for progression-free survival and 29.1 months overall; reoperation after recurrence notably improved survival time.
  • Key factors influencing survival included tumor spread before initial surgery, the number of adjuvant temozolomide cycles received, and radiotherapy; extending the Stupp regimen with more temozolomide cycles could enhance outcomes for patients.

Article Abstract

Epithelioid glioblastoma (Ep-GBM) is a rare variant of glioblastoma characterized by a high recurrence rate and poor prognosis. Currently, there is no established standard treatment for Ep-GBM. Therefore, we identified 58 Ep-GBM cases to investigate these characteristics and identify the possible prognostic factors of survival. There were 30 male and 28 female patients with a median age of 39 years. Headaches and dizziness were the most common clinical symptom. The tumor is most frequently located in the temporal lobe (36.2%). The positivity rate for BRAF-V600E is 56.9% (33/58), for MGMT is 56.9% (33/58), and for INI-1 is 75% (30/40). Tumor recurrence was observed in 39 patients. The median progression-free survival (PFS) of all patients was 12.7 months, while the median overall survival (OS) was 29.1 months. Additionally, the median survival time after recurrence was 14.3 months. Both univariate and multivariate COX regression analyses revealed that individuals who received more than six cycles of adjuvant oral temozolomide experienced a longer median PFS compared to those who received fewer cycles. Characteristics associated with poorer PFS included tumor dissemination prior to initial surgery. Additionally, both analyses identified tumor dissemination, radiotherapy and adjuvant oral temozolomide as predictors of OS. Notably, for patients with recurrent Ep-GBM, reoperation was shown to significantly increase survival time after recurrence. In conclusion, the standard Stupp regimen is also applicable to patients with Ep-GBM, extending adjuvant oral temozolomide could further improve survival for Ep-GBM patients, reoperation may also prolong survival for recurrent Ep-GBM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464587PMC
http://dx.doi.org/10.1007/s10143-024-02957-1DOI Listing

Publication Analysis

Top Keywords

adjuvant oral
12
oral temozolomide
12
survival
8
patients
8
patients epithelioid
8
epithelioid glioblastoma
8
patients median
8
569% 33/58
8
median survival
8
survival time
8

Similar Publications

Objectives: We investigate if sublingual space invasion (SLI) determined on magnetic resonance imaging confers differences in clinicopathological manifestations and treatment outcomes of oral tongue squamous cell carcinoma (OTSCC).

Study Design: Retrospective cohort study.

Setting: Tertiary Academic Medical Center.

View Article and Find Full Text PDF

The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.

Oral Oncol

December 2024

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Introduction: Studies reported inferior outcomes when radiotherapy starts >6-8 weeks post-surgery for head and neck squamous cell carcinoma (HNSCC) but are limited due to time variable dichotomization. We assessed the relationship between survival and the time between surgery and radiotherapy as a continuous variable, hypothesising there would be no change in patients' survival at 6-8 weeks post-surgery.

Methods/materials: Inclusion criteria: patients with HNSCC who underwent surgery and adjuvant (chemo)radiotherapy, Jan 2014-Dec 2020.

View Article and Find Full Text PDF

Objectives: Muscle loss after radiotherapy is associated with poorer survival in patients with oral cavity squamous cell carcinoma (OCSCC). However, the threshold of muscle loss remains unclear. This study aimed to utilize explainable artificial intelligence to identify the threshold of muscle loss associated with survival in OCSCC.

View Article and Find Full Text PDF

This research work was designed to develop efficient Diosgenin (DGN) loaded biodegradable nanoparticles (DGN-NPs) for treating rheumatoid arthritis. The DGN-NPs were synthesized by ionic-gelation method using chitosan as a biodegradable polymer and in-vitro release study was performed followed by kinetics study. DGN-NPs had an average size of 290 nm, zeta potential of +11.

View Article and Find Full Text PDF

The aim of this study was to investigate the scientific evidence regarding the effectiveness of modified-ILIB (intravascular laser irradiation of blood) in the control of systemic conditions and/or oral changes during dental care. This systematic literature review study aimed to answer the question, "Is modified-ILIB an effective adjuvant therapy in the control of systemic conditions and/or oral changes in children and adults during dental treatment?". The protocol for this systematic review was registered in the PROSPERO database under number CRD42023493800.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!